Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Receivables for 3 consecutive years, with -$12000.0 as the latest value for Q4 2025.

  • For Q4 2025, Change in Receivables rose 89.38% year-over-year to -$12000.0; the TTM value through Dec 2025 reached -$79000.0, up 86.33%, while the annual FY2025 figure was -$79000.0, 86.33% up from the prior year.
  • Change in Receivables hit -$12000.0 in Q4 2025 for Artiva Biotherapeutics, down from $49000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $383000.0 in Q2 2024 and bottomed at -$888000.0 in Q4 2023.
  • Average Change in Receivables over 3 years is -$162500.0, with a median of -$96500.0 recorded in 2023.
  • Year-over-year, Change in Receivables plummeted 691.25% in 2024 and then surged 140.93% in 2025.
  • Artiva Biotherapeutics' Change in Receivables stood at -$888000.0 in 2023, then skyrocketed by 87.27% to -$113000.0 in 2024, then skyrocketed by 89.38% to -$12000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$12000.0, $49000.0, and -$204000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.